Revance Therapeutics, Inc. (NASDAQ:RVNC – Get Rating)’s share price reached a new 52-week high during trading on Wednesday after Piper Sandler raised their price target on the stock from $29.00 to $40.00. Piper Sandler currently has an overweight rating on the stock. Revance Therapeutics traded as high as $34.95 and last traded at $34.84, with a volume of 648158 shares. The stock had previously closed at $34.68.
RVNC has been the subject of a number of other reports. Guggenheim boosted their price target on Revance Therapeutics to $36.00 in a report on Tuesday, November 15th. HC Wainwright upped their price objective on shares of Revance Therapeutics from $29.00 to $42.00 and gave the stock a “buy” rating in a research report on Thursday, January 26th. Morgan Stanley increased their price objective on Revance Therapeutics from $25.00 to $26.00 and gave the company an “equal weight” rating in a research note on Tuesday, January 24th. Barclays upped their price objective on shares of Revance Therapeutics from $35.00 to $37.00 and gave the company an “overweight” rating in a report on Wednesday, November 16th. Finally, StockNews.com upgraded shares of Revance Therapeutics from a “sell” rating to a “hold” rating in a report on Monday. Three analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $39.64.
Insider Activity at Revance Therapeutics
In other Revance Therapeutics news, CFO Tobin Schilke sold 1,000 shares of the company’s stock in a transaction dated Friday, January 20th. The stock was sold at an average price of $31.00, for a total transaction of $31,000.00. Following the sale, the chief financial officer now owns 57,877 shares in the company, valued at approximately $1,794,187. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 5.10% of the stock is currently owned by company insiders.
Hedge Funds Weigh In On Revance Therapeutics
Revance Therapeutics Price Performance
The firm has a 50 day moving average of $23.98 and a two-hundred day moving average of $23.02. The company has a debt-to-equity ratio of 2.60, a quick ratio of 5.33 and a current ratio of 5.56.
Revance Therapeutics (NASDAQ:RVNC – Get Rating) last posted its earnings results on Tuesday, November 8th. The biopharmaceutical company reported ($1.17) earnings per share for the quarter, missing the consensus estimate of ($0.85) by ($0.32). The business had revenue of $29.02 million for the quarter, compared to analysts’ expectations of $28.76 million. Revance Therapeutics had a negative return on equity of 461.54% and a negative net margin of 251.92%. As a group, sell-side analysts anticipate that Revance Therapeutics, Inc. will post -4.26 earnings per share for the current fiscal year.
About Revance Therapeutics
Revance Therapeutics, Inc is a clinical stage biotechnology company, which engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for aesthetic and therapeutic indications including facial wrinkles and muscle movement disorders.
- Get a free copy of the StockNews.com research report on Revance Therapeutics (RVNC)
- Allegro Microsystems Is A Well-Positioned Semiconductor Stock
- Scotts Miracle-Gro Hits Bottom, Reversal In Play
- Altria is a Great Recession Stock, Long-Term Outlook Uncertain
- Novavax Shares Jumped in January While Others Slipped
- Boeing Produces the Last 747 Ever, What’s Next?
Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.